rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    GLUE
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Monte Rosa: A Risky Contrarian Buy As Market Abandons Bull Thesis

      Monte Rosa Therapeutics is rated a risky Buy, as $580 million cash leaves its pipeline worth about $215 million, with MRT-6160 and MRT-2359 catalysts.

      Nov 17Seeking AlphaGLUE
      Monte Rosa Therapeutics: The Market Is Punishing NEK7 For IL-6's Failure (NASDAQ:GLUE)
      Nov 17Seeking AlphaGLUE
      Monte Rosa Therapeutics (GLUE) Stock Fair Value Edges Lower As Analysts Weigh NEK7 Promise And Risk

      The blended fair value estimate for Monte Rosa Therapeutics has shifted from US$28.00 to US$25.38, reflecting updated assumptions in the latest analyst work. Recent Street commentary links this adjustment to a mix of optimism around MRT-8102 and NEK7 progress, along with caution on execution risk and current valuation, which has led some analysts to trim price targets. Read on to see how these moving pieces fit together and how to track the evolving Monte Rosa Therapeutics story from...

      Nov 11Yahoo FinanceGLUE
      Monte Rosa at Guggenheim healthcare conference: pipeline gains momentum
      Nov 9Investing.comGLUE
      Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2026 on the Potential of MRT-8102 in Gout

      NEK7-directed molecular glue degrader inhibited NLRP3 inflammasome activation in human experimental systems and demonstrated anti-inflammatory activity in a rabbit model of gouty arthritis GEMINI-1, a Phase 2 study of MRT-8102 in patients with gout, is expected to initiate in Q4 2026, with initial data expected in H2 2027 Poster presentation on November 9, 2026, at 10:30 a.m. ET BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology

      Nov 9Yahoo FinanceGLUE
      Monte Rosa Therapeutics (GLUE) Tops Q3 Earnings and Revenue Estimates
      Nov 5Yahoo FinanceGLUE
      Monte Rosa Therapeutics: Q3 Earnings Snapshot
      Nov 5Yahoo FinanceGLUE
      Monte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates
      Nov 5Yahoo FinanceGLUE
      Monte Rosa Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Nov 3Yahoo FinanceGLUE
      Wall Street Analysts See a 152.87% Upside in Monte Rosa Therapeutics (GLUE): Can the Stock Really Move This High?
      Nov 3Yahoo FinanceGLUE
      Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

      BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences: Guggenheim's 3rd Annual Healthcare Innovation Conference (Boston, MA) – fireside chat, November 9, 2026, at 8:00 a.m. ETUBS Global Biopharma Conference 2026 (London, UK) – fireside chat, November 16, 2026, at 12:00 p.m. G

      Nov 2Yahoo FinanceGLUE
      Monte Rosa Therapeutics (GLUE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
      Oct 29Yahoo FinanceGLUE
      Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
      Oct 28Yahoo FinanceGLUE
      Are Options Traders Betting on a Big Move in Monte Rosa Therapeutics Stock?
      Oct 23Yahoo FinanceGLUE
      UBS Adjusts Price Target on Monte Rosa Therapeutics to $19 From $17, Maintains Buy Rating
      Oct 12Yahoo FinanceGLUE
      Monte Rosa's MRT-8102 Shows Biomarker Gains in GFORCE-1 Study

      Monte Rosa Therapeutics (NASDAQ:GLUE) reported results from GFORCE-1, a Phase I study of its NEK7-directed molecular glue degrader MRT-8102 in participants with elevated cardiovascular risk. The company said the four-week dosing study showed sustained degradation of NEK7, reductions in inflammatory

      Oct 6Yahoo FinanceGLUE
      Monte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degrader MRT-8102 in Cardiovascular Disease Risk - Slideshow (NASDAQ:GLUE) 2026-10-05

      2026-10-05. The following slide deck was published by Monte Rosa Therapeutics, Inc.

      Oct 5Seeking AlphaGLUE
      H.C. Wainwright reiterates Monte Rosa stock rating on trial data
      Oct 5Investing.comGLUE
      Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE) and Cullinan Management (CGEM)

      Detailed price information for Monte Rosa Therapeutics Inc (GLUE-Q) from The Globe and Mail including charting and trades.

      Oct 3The Globe and MailGLUE
      Guggenheim Sticks to Its Buy Rating for Monte Rosa Therapeutics (GLUE)

      Detailed price information for Monte Rosa Therapeutics Inc (GLUE-Q) from The Globe and Mail including charting and trades.

      Oct 3The Globe and MailGLUE
      Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of inducement equity awards to five newly hired non-executive employees as a material inducement to commencing their employment with the Company. The employees received, in the aggregate, non-qualified stock options to purchase 86,725 shares of Monte Rosa Therapeutics common stock,

      Oct 2Yahoo FinanceGLUE
      Monte Rosa Therapeutics Investigational Drug Shows Potential for Cardiovascular Disease - Monte Rosa Ther

      Monte Rosa Therapeutics reports positive Phase 1 trial data for MRT-8102 and outlines upcoming Phase 2 studies in inflammatory diseases.

      Oct 1BenzingaGLUE
      Monte Rosa posts trial data for anti-inflammatory drug (GLUE)
      Oct 1Seeking AlphaGLUE
      Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk

      In obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1-driven inflammatory diseases, normalized multiple atherosclerotic cardiovascular disease (ASCVD) pathogenic drivers of local plaque inflammation, thrombosis, and systemic inflammation Robust and sustained NEK7 degradation observed across 5 mg, 20 mg, and 40 mg once-daily dose levels, with similar biomarker reductions at all three doses

      Oct 1Yahoo FinanceGLUE
      Monte Rosa Therapeutics Shares Surge Premarket - Monte Rosa Therapeutics (NASDAQ:GLUE)

      Monte Rosa Therapeutics shares surged 20.03% premarket as investors awaited clinical data from its experimental heart-risk drug.

      Oct 1BenzingaGLUE
      Why is Monte Rosa Therapeutics stock surging 20% today?
      Oct 1Investing.comGLUE
      HC Wainwright Initiates Monte Rosa Therapeutics at Buy With $25 Price Target
      Oct 1Yahoo FinanceGLUE
      12 Health Care Stocks Moving In Wednesday's After-Market Session - Monte Rosa Therapeutics (NASDAQ:GLUE),

      Gainers Monte Rosa Therapeutics (NASDAQ:GLUE) stock rose 9.7% to $13.09 during Wednesday's after-market session. The company's market cap stands at $1.0 billion. Filana Therapeutics (NASDAQ:FLNA) shares rose

      Sep 30BenzingaGLUE
      Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk

      Conference call and webcast to be held at 8:00 a.m. ET on Oct. 1, 2026BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and webcast on Thursday, October 1, at 8:00 a.m. ET. The webcast presentation will review clinical results from the GFORCE-1 Phase 1 study of the NEK7-directed MGD MRT-8102

      Sep 30Yahoo FinanceGLUE
      Monte Rosa Therapeutics: Ziltivekimab's Failures, Additional Thoughts On MRT-8102 And MRT-6160 (NASDAQ:GLUE)
      Sep 29Seeking AlphaGLUE
      Novartis (NVS) Just Handed Monte Rosa (GLUE) A $50M Milestone

      On September 8, Monte Rosa Therapeutics (NASDAQ:GLUE) announced that Novartis (NYSE:NVS), its partner on a VAV1-targeted drug, had dosed the first patient in a Phase 2 trial of MRT-6160 (DDY391) for people with Sjögren’s disease. That single clinical checkpoint triggers a $50 million payment to Monte Rosa and marks just the first step in a […]

      Sep 13Yahoo FinanceGLUE
      Monte Rosa Therapeutics at Wells Fargo: pipeline gains and long cash runway
      Sep 10Investing.comGLUEWFC
      Analysts’ Top Healthcare Picks: IDEAYA Biosciences (IDYA), Monte Rosa Therapeutics (GLUE)

      Detailed price information for Monte Rosa Therapeutics Inc (GLUE-Q) from The Globe and Mail including charting and trades.

      Sep 10The Globe and MailGLUEIDYA
      Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)

      Phase 2 study to be conducted in participants with Sjögren’s disease Novartis conducting study under global exclusive development and commercialization license agreement with Monte Rosa Monte Rosa to receive milestone payment based on first patient visit of Phase 2 clinical study Additional studies expected to evaluate the potential of MRT-6160 (DDY391) across immune-mediated diseases; Monte Rosa eligible for additional Phase 2 study initiation milestones BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE)

      Sep 8Yahoo FinanceGLUE
      Monte Rosa: High-Stakes Drug Pipeline Balanced By A Fortress Balance Sheet (NASDAQ:GLUE)

      Monte Rosa made a strategic move to partner with Novartis, which now has the responsibility for Phase 2 clinical development. Read why GLUE stock is a buy.

      Sep 3Seeking AlphaGLUE
      Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Sep 2Yahoo FinanceGLUE
      Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

      BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences: Wells Fargo 21st Annual Healthcare Conference (Boston, MA) – Markus Warmuth, M.D., Chief Executive Officer, to participate in a fireside chat, September 10, 2026, at 12:45 p.m. ETMorgan Stanley 24th Annual Global Healthc

      Sep 1Yahoo FinanceGLUE
      Why is Monte Rosa Therapeutics stock sliding today?
      Aug 24Investing.comGLUE
      Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer

      Study will evaluate PSA and RECIST response, duration of response, radiographic progression-free survival (rPFS), and safety Updated data from the initial Phase 1/2 study of MRT-2359 plus enzalutamide in patients with advanced CRPC expected by end of year BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that the first patient has been dosed

      Aug 24Yahoo FinanceGLUE

      This is the newest page. Registered accounts read further back.